Depression and insulin resistance: Applications to polycystic ovary syndrome

Clinical Obstetrics and Gynecology

Volumn 47, Issue 3, 2004, Pages 592-596

  Brown, Ann J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; BEHAVIOR THERAPY; COGNITIVE THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DIABETES CONTROL; FEMALE; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PREVALENCE; RATING SCALE; SELF CARE; SELF MONITORING;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME;

EID: 4644240985     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000126135.73066.89     Document Type: Conference Paper

References (14)

1. Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes type 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54:317-329.
2. Nichols GA, Brown JB. Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. Diabetes Care. 2003;26:744-749.
3. Lustman PJ, Freedland KE, Griffith SL, et al. Fluoxetine for depression in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2000;23:618-623.
4. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med. 1997;59:241-250.
5. Lustman PJ, Griffith LS, Freedland KE, et al, Cognitive behavioral therapy for depression in type 2 diabetes mellitus, Ann Int Med. 1998;129:613-621.
6. Carnethon MR, Kinder LS, Fair JM, et al. Symptoms of depression as a risk factor for incident diabetes: findings from the National Health and Nutrition Examination Epidemiologic Follow-up Study, 1971-1992. Am J Epidemiol. 2003;158:416-423.
7. Eaton WW. Depression and risk for onset of type 2 diabetes: a prospective population based study. Diabetes Care. 1996;19:1097-1102.
8. Kawakami N, Takatsuka N, Shimizu H, et al. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care. 1999;22:1071-1076.
9. Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism. 2000;49:1255-1260.
10. Ramasubbu R. Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases. Medical Hypothesis. 2002;59:537-551.
11. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women in the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-3082.
12. Legro RS, Kunselman A, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;94:165-169.
13. Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2003;88:5801-5807.
14. Rasgon NL, Rao RC, Hwang S, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord. 2003;74:299-304.